Lung Cancer Diagnosis & Treatment Market
Global Lung Cancer Diagnosis & Treatment Market Size, Share & Trends Analysis Report By Type (Non-Small-Cell Lung Cancer, and Small-Cell-Lung Cancer) By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, and Others) By Diagnosis (CT Scan, X-Rays, Lung Cancer Screening, Needle Biopsy, and Others) Forecast 2021-2027 Update Available - Forecast 2024-2030
The global market for lung cancer diagnosis & treatment is projected to have a CAGR of around 7.2% during the forecast period. Lung cancer occurs when cells of the lung become abnormal and begin to grow out of control. As more cancer cells develop, they form into a tumor and spread to other areas of the body. Several factors are being considered for the cause of lung cancer such as rising pollution due to the amount of carbon particles inhaled by humans. Robust healthcare expenditure within the developed countries, government initiatives for lung cancer, and rising cases of smoking are some of the major factors that fuel the growth of the market. According to the Centers for Disease Control and Prevention, lung cancer is the leading cause of cancer death and the second most common cancer among both men and women in the United States. Every year around 221,000 people in the United States develops lung cancer, and about 146,000 people die from this disease. Additionally, according to the American Cancer Society’s estimates for lung cancer in the US, in 2021, there are 235,760 new cases of lung cancer, and about 131,880 mortalities from lung cancer found.
Moreover, the challenges associated with the market which hampers the growth of the market are the high cost of the treatment, fear associated with a lung transplant, and adverse effects of drugs during the treatment. The R&D in mixed therapies such as Chemotherapy with radiation therapy and growing FDA approvals for cancer-treating drugs are projected to create lucrative opportunities in the market, which will further drive the growth during the forecast period. For instance, in Feb 2021, Merck announced that the US Food and Drug Administration (FDA) has approved TEPMETKO (tepotinib) drug for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
Segmental Outlook
The global lung cancer diagnosis & treatment market is segmented based on type, treatment, and diagnosis. On the basis of type, the market is bifurcated into non-small cell lung cancer, and small-cell lung cancer. Among these, non-small cell lung cancer is projected to be the fastest-growing segment during the forecast period. The rising consumption of cigarettes is the main cause of this type of lung cancer, which will lead to the demand for the treatment that will further be projected to drive the market. Based on treatment the market is segregated into chemotherapy, targeted therapy, immunotherapy, radiation therapy, and others. Similarly, based on diagnosis, the market is categorized into CT-scan, X-rays, lung cancer screening, needle biopsy, and others.
Global Lung Cancer Diagnosis & Treatment Market Share by Treatment, 2020 (%)
The chemotherapy segment holds the largest share in the global lung cancer diagnosis & treatment market
Based on treatment, the chemotherapy segment dominated the market in 2020, and it is anticipated to grow at a significant CAGR during the forecast period. Chemotherapy is used to treat small cell lung cancer and it is the most advised therapy before surgery to treat small-cell lung cancer. The chemotherapy uses Cytotoxic (cell-killing) medications to kill cancer cells. It is often used to treat lung cancer either alone or in conjunction with other modes of treatment. Chemotherapy coupled with radiation therapy supports the treatment of lung cancer in an effective manner. Chemotherapy supports keeping the cancer cells small and radiation therapy enabled to destroy of the cancer cells. The rising prevalence of lung cancer across the globe creates the demand for advanced treatments such as chemotherapy, which further drives the market growth.
Regional Outlook
Geographically, the global lung cancer diagnosis & treatment market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). Among these, the Asia-Pacific market is considered to be the fastest-growing market globally. The rise in the number of cancer patients in the Asia-Pacific is considered to rise eventually propelling the lung cancer diagnostics and therapeutics market growth.
Global Lung Cancer Diagnosis & Treatment Market Growth, by Region 2021-2027
North America dominates the lung cancer diagnosis & treatment market
Geographically, North America projected to have the largest share in the global lung cancer diagnosis and treatment market during the forecast period. The factors that augmented the growth of the region include rising smoking prevalence level, significant funding for cancer research and high penetration of technically advanced products. Apart from this, the rising awareness programs by the government, high healthcare expenditure, and development in technology are projected to contribute towards the development of the market in the region. The US contributes a major share in the North American lung cancer diagnosis & treatment market owing to the high patient’s base, and well-developed health infrastructure coupled with advanced treatments and therapies.
Market Players Outlook
The key players in the lung cancer diagnosis & treatment market contributing significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market include F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Co., Pfizer Inc., Sanofi, Eli Lilly and Co., Merck & Co. Inc., Novartis AG, AstraZeneca Plc, GlaxoSmithKline plc., among others. These market players adopt different marketing strategies such as mergers and acquisitions, R&D, product launches, and geographical expansions so on. For instance, in December 2019, Merck & Co., Inc. had acquired ArQule Inc. for $2.7 billion. By acquiring ArQule Inc., and its business focused on the development of kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases, the company expanded its product offering in cancer-treating drugs portfolio.
The Report Covers
- Market value data analysis of 2020 and forecast to 2027.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global lung cancer diagnosis & treatment market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Lung Cancer Diagnosis & Treatment Industry
• Recovery Scenario of Global Lung Cancer Diagnosis & Treatment Industry
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.2. Key Strategy Analysis
3.3. Impact of Covid on key players
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Lung Cancer Diagnosis & Treatment Market, By Type
5.1.1. Non-Small Cell Lung Cancer
5.1.2. Small Cell Lung Cancer
5.2. Global Lung Cancer Diagnosis & Treatment Market, By Treatment
5.2.1. Chemotherapy
5.2.2. Targeted Therapy
5.2.3. Immunotherapy
5.2.4. Radiation Therapy
5.2.5. Others (Surgery)
5.3. Global Lung Cancer Diagnosis & Treatment Market, By Diagnosis
5.3.1. CT-Scan
5.3.2. X-Rays
5.3.3. Lung Cancer Screening
5.3.4. Needle Biopsy
5.3.5. Others (Bronchoscopy, Sputum Cytology)
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Russia
6.2.7. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. South Korean
6.3.5. Rest of Asia-Pacific
6.4. Rest of the World
6.4.1. Latin America
6.4.2. Middle East& Africa
7. Company Profiles
7.1. AbbVie Inc.
7.2. AstraZeneca Plc
7.3. Bayer AG
7.4. Boehringer Ingelheim International GmbH
7.5. Bristol-Myers Squibb Co.
7.6. Daiichi Sankyo Co, Ltd.
7.7. Eisai Co., Ltd.
7.8. Eli Lilly and Co.
7.9. GlaxoSmithKline plc.
7.10. Merck & Co., Inc.,
7.11. Myriad Genetics, Inc.
7.12. Novartis International AG
7.13. Pfizer Inc.
7.14. F. Hoffmann-La Roche Ltd.
7.15. Sanofi S.A.
7.16. Teva Pharmaceutical Industries Ltd.
7.17. Thermo Fisher Scientific, Inc.
7.18. QIAGEN GmbH
1. GLOBAL LUNG CANCER DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
2. GLOBAL NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
3. GLOBAL SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
4. GLOBAL LUNG CANCER DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
5. GLOBAL CHEMOTHERAPY FOR LUNG CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
6. GLOBAL TARGETED THERAPY FOR LUNG CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
7. GLOBAL IMMUNOTHERAPY FOR LUNG CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
8. GLOBAL RADIATION THERAPY FOR LUNG CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
9. GLOBAL OTHERS THERAPY FOR LUNG CANCER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
10. GLOBAL LUNG CANCER DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
11. GLOBAL CT SCAN IN LUNG CANCER DIAGNOSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
12. GLOBAL X-RAYS FOR LUNG CANCER DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
13. GLOBAL LUNG CANCER SCREENING FOR LUNG CANCER DIAGNOSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
14. GLOBAL NEEDLE BIOPSY FOR LUNG CANCER DIAGNOSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
15. GLOBAL OTHERS LUNG CANCER DIAGNOSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
16. NORTH AMERICAN LUNG CANCER DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY,2020-2027 ($ MILLION)
17. NORTH AMERICAN LUNG CANCER DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE,2020-2027 ($ MILLION)
18. NORTH AMERICAN LUNG CANCER DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS BY BY TREATMENT, 2020-2027 ($ MILLION)
19. NORTH AMERICAN LUNG CANCER DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS BY BY DIAGNOSIS, 2020-2027 ($ MILLION)
20. EUROPEAN LUNG CANCER DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
21. EUROPEAN LUNG CANCER DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE,2020-2027 ($ MILLION)
22. EUROPEAN LUNG CANCER DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT,2020-2027 ($ MILLION)
23. EUROPEAN LUNG CANCER DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
24. ASIA-PACIFIC LUNG CANCER DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
25. ASIA-PACIFIC LUNG CANCER DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE,2020-2027 ($ MILLION)
26. ASIA-PACIFIC LUNG CANCER DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
27. ASIA-PACIFIC LUNG CANCER DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
28. REST OF THE WORLD LUNG CANCER DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
29. REST OF THE WORLD LUNG CANCER DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
30. REST OF THE WORLD LUNG CANCER DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
31. REST OF THE WORLD LUNG CANCER DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL LUNG CANCER DIAGNOSIS & TREATMENT MARKET, 2020-2027 (% MILLION)
2. IMPACT OF COVID-19 ON GLOBAL LUNG CANCER DIAGNOSIS & TREATMENT MARKET BY SEGMENT, 2020-2027 (% MILLION)
3. RECOVERY OF GLOBAL LUNG CANCER DIAGNOSIS & TREATMENT MARKET, 2020-2027 (%)
4. GLOBAL LUNG CANCER DIAGNOSIS & TREATMENT MARKET SHARE BY TYPE,2020 VS 2027 (%)
5. GLOBAL LUNG CANCER DIAGNOSIS & TREATMENT MARKET SHARE BY TREATMENT,2020 VS 2027 (%)
6. GLOBAL LUNG CANCER DIAGNOSIS & TREATMENT MARKET SHARE BY DIAGNOSIS, 2020 VS 2027 (%)
7. GLOBAL LUNG CANCER DIAGNOSIS & TREATMENT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
8. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
9. GLOBAL SMALL CELL LUNG CANCER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
10. GLOBAL CHEMOTHERAPY FOR LUNG CANCER TREATMENT MARKET SHARE BY TYPE, 2020-2027 ($ MILLION)
11. GLOBAL TARGETED THERAPY FOR LUNG CANCER TREATMENT MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
12. GLOBAL IMMUNOTHERAPY FOR LUNG CANCER TREATMENT MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
13. GLOBAL RADIATION THERAPY FOR LUNG CANCER TREATMENT MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
14. GLOBAL OTHERS THERAPY FOR LUNG CANCER TREATMENT MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
15. GLOBAL CT SCAN FOR LUNG CANCER DIAGNOSIS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
16. GLOBAL X-RAYS FOR LUNG CANCER DIAGNOSIS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
17. GLOBAL LUNG CANCER SCREENING FOR LUNG CANCER DIAGNOSIS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
18. GLOBAL NEEDLE BIOPSY FOR LUNG CANCER DIAGNOSIS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
19. GLOBAL OTHERS LUNG CANCER DIAGNOSIS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
20. US LUNG CANCER DIAGNOSIS & TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
21. CANADA LUNG CANCER DIAGNOSIS & TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
22. UK LUNG CANCER DIAGNOSIS & TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
23. FRANCE LUNG CANCER DIAGNOSIS & TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
24. GERMANY LUNG CANCER DIAGNOSIS & TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
25. ITALY LUNG CANCER DIAGNOSIS & TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
26. SPAIN LUNG CANCER DIAGNOSIS & TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
27. RUSSIALUNG CANCER DIAGNOSIS & TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
28. REST OF EUROPE LUNG CANCER DIAGNOSIS & TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
29. INDIA LUNG CANCER DIAGNOSIS & TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
30. CHINA LUNG CANCER DIAGNOSIS & TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
31. JAPAN LUNG CANCER DIAGNOSIS & TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
32. SOUTH KOREA LUNG CANCER DIAGNOSIS & TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
33. REST OF ASIA-PACIFIC LUNG CANCER DIAGNOSIS & TREATMENT MARKET SIZE, 2020-2027 ($ MILLION)
34. REST OF THE WORLD LUNG CANCER DIAGNOSIS & TREATMENT MARKET SIZE, 2021-2027($ MILLION
